World Market for Prescription Generic Drugs, 6th Edition

Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics.

Kalorama Information's World Market for Prescription Generic Drugs, 6th Edition is your guide to this formidable and important participant in the complex world of healthcare. Included are market size and forecast revnues for:

Allergy and Respiaratory Drugs

Analgesics, NAIDS, and Antirheumatic Drugs

Anesthesia Drugs

Anti-Infectives

Cancer Drugs

Cardiovascular Drugs

Central Nervous System and Psychotherapeutic Drugs

Gastrointestinal Drugs

Ophthalmic Drugs

This report is the result of primary research and secondary research. Interviews with experts in the generic industry form the basis of this report. Research was conducted from available company reports, trade publications and medical and government databases. Interviews with experts are the source of models.

For each drug segment, the report provides:

Estimated Generic Market Size

Forecast to 2012

Recent ANDA Approvals

World and US Market Share

Company Profiles

Knowledge of the issues that face the generics industry is essential to understanding the market. The report discusses the following trends:

Legislative Issues

Big Pharma Tactics

Authorized Generics

Generic Biologics

Medicaid Generic Drug Reimbursement

The Elderly

Confusion in Generic Names

Broadening Generic Horizons

International Generic Drug Issues

Indian Drug Makers

Industry Consolidation

New Generic Giants

Patent Issues

Generic Companies Increasingly Aggressive

Patent Reform

Generic Growth

Generic Statins

Cost

Generics Improve Compliance

Generic Drug Sampling

Marketing executives, business development managers and brand and generic pharmaceutical companies, consultants and investors are among those who will benefit from this report.